Overview

Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Primary : effect on weight loss and weight maintenance over 9 months when prescribed with a hypocaloric diet in obese patients. Secondary : effect on HDL-Cholesterol, triglycerides, fasting-insulin, fasting glucose, waist circumference - safety and tolerability
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Rimonabant